Diaceutics PLC
LSE:DXRX

Watchlist Manager
Diaceutics PLC Logo
Diaceutics PLC
LSE:DXRX
Watchlist
Price: 118.5 GBX
Market Cap: 100.5m GBX
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+53%
Revenue
Forecast
+4%
Operating Income
Forecast
+862%
Net Income
Forecast
+4%

Wall Street
Price Targets

DXRX Price Targets Summary
Diaceutics PLC

Wall Street analysts forecast DXRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DXRX is 203.39 GBX with a low forecast of 181.8 GBX and a high forecast of 236.25 GBX.

DXRX Lowest Forecast
Wall Street Target
181.8 GBX
53% Upside
DXRX Average Forecast
Wall Street Target
203.39 GBX
72% Upside
DXRX Highest Forecast
Wall Street Target
236.25 GBX
99% Upside
Lowest
Price Target
181.8 GBX
53% Upside
Average
Price Target
203.39 GBX
72% Upside
Highest
Price Target
236.25 GBX
99% Upside
Diaceutics PLC Competitors:
Price Targets
AZTA
Azenta Inc
28% Upside
S
237690
ST Pharm Co Ltd
51% Upside
688222
HitGen Inc
7% Upside
LONN
Lonza Group AG
18% Upside
AZTA
Azenta Inc
28% Upside
S
237690
ST Pharm Co Ltd
51% Upside
688222
HitGen Inc
7% Upside
LONN
Lonza Group AG
18% Upside
STVN
Stevanato Group SpA
13% Upside
CHEMM
Chemometec A/S
7% Upside
BIOT
Biotage AB
3% Upside
LAB
Standard BioTools Inc
104% Upside

Revenue
Forecast

Revenue Estimate
Diaceutics PLC

For the last 7 years the compound annual growth rate for Diaceutics PLC's revenue is 23%. The projected CAGR for the next 3 years is 22%.

23%
Past Growth
22%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Diaceutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
14%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Diaceutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
18%
Average Beat
What are analyst estimates?

See Also

Summary
DXRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
DXRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DXRX stock valuation using valuation multiples.
Wall Street Estimates
DXRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DXRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is DXRX's stock price target?
Price Target
203.39 GBX

According to Wall Street analysts, the average 1-year price target for DXRX is 203.39 GBX with a low forecast of 181.8 GBX and a high forecast of 236.25 GBX.

What is Diaceutics PLC's Revenue forecast?
Projected CAGR
22%

For the last 7 years the compound annual growth rate for Diaceutics PLC's revenue is 23%. The projected CAGR for the next 3 years is 22%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 264,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.